Dose-dependent effects of atorvastatin in the hospitalisation period of myocardial infarction

QR Code

Dose-dependent effects of atorvastatin in the hospitalisation period of myocardial infarction

Aim. To compare the dynamic effects of atorvastatin doses 20 mg and 40 mg on lipid profile, insulin resistance markers, adipokines, prothrombotic, and proinflammatory status in myocardial infarction (MI) patients during the hospitalisation period. Material and methods. The study included 42 patients...

Full description

Saved in:

Bibliographic Details
Main Authors:	O. L. Barbarash, O. V. Gruzdeva, O. E. Akbasheva, T. S. Fedorova, A. A. Silonova, E. I. Palicheva, E. G. Uchasova, V. N. Karetnikova, V. V. Kashtalap
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2013-06-01
Series:	Российский кардиологический журнал
Subjects:	myocardial infarction atorvastatin lipids insulin resistance adipokines
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/392
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

RELATIONSHIP OF OBESITY PARAMETERS AND ADIPOKINES WITH THE RISK OF 2ND TYPE DIABETES DEVELOPMENT IN A YEAR AFTER MYOCARDIAL INFARCTION
by: O. V. Gruzdeva, et al.
Published: (2015-04-01)

CLINICAL AND BIOCHEMICAL PREDICTORS OF DIABETES MELLITUS MANIFESTATION AFTER MYOCARDIAL INFARCTION
by: O. L. Barbarash, et al.
Published: (2014-03-01)

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES
by: A. N. Meshkov
Published: (2016-01-01)

Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension
by: N. B. Amirov, et al.
Published: (1970-01-01)

INSULIN RESISTANCE MARKERS IN PATIENTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
by: O. V. Gruzdeva, et al.
Published: (2011-12-01)

Nephroprotective effect of atorvastatin at a dose of 80 mg in patients with ST-segment elevation myocardial infarction with an invasive treatment strategy
by: A. D. Gavrilko, et al.
Published: (2023-11-01)

Effectiveness, safety, and endothelial function effects of atorvastatin lipid-lowering therapy in coronary heart disease patients undergoing percutaneous coronary intervention
by: M. P. Mal’gina, et al.
Published: (2007-06-01)

ANTIATHEROGENIC AND PLEIOTROPIC ACTIVITY OF VARIOUS DOSES OF ATORVASTATIN IN PATIENTS WITH ISCHEMIC STROKE
by: M. G. Bubnova, et al.
Published: (2013-08-01)

The role of immune cells in the development of adipose tissue dysfunction in cardiovascular diseases
by: E. G. Uchasova, et al.
Published: (2019-05-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

Analysis of the binary mixtures of amlodipine and atorvastatin by chemometric-spectophotometric method
by: Hayrettin Bulum, et al.
Published: (2025-06-01)

Long-term low-dose atorvastatin therapy and prevention of macroangiopathy complications in elderly patients with Type 2 diabetes mellitus
by: G. A. Batrak, et al.
Published: (2010-06-01)

The Interplay Between Body Weight and the Onset of Puberty
by: Alexandros K. Kythreotis, et al.
Published: (2025-05-01)

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA
by: J. E. Semyonova, et al.
Published: (2015-12-01)

USE OF DISSOLUTION TEST FOR EVALUATION OF PHARMACEUTICAL EQUIVALENCE OF ATORVASTATIN GENERICS
by: O. V. Druzhininskaya, et al.
Published: (2019-01-01)

ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE
by: M. V. Solodun, et al.
Published: (2015-09-01)

Aggressive statin therapy in acute coronary syndrome: therapeutic potential of atorvastatin in the daily dose of 80 mg
by: A. N. Britov
Published: (2009-12-01)

Possibilities of atorvastatin loading dose using for the prevention of perioperative myocardial damage in patients with stable coronary artery disease
by: A. S. Ragozina, et al.
Published: (2019-11-01)

Anti-inflammatory effects of low- and high-dose atorvastatin therapy in patients with coronary heart disease and rheumatoid arthritis
by: V. S. Tutunov, et al.
Published: (2008-10-01)

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

ATORVASTATIN IN ACUTE AND CHRONIC KINDS OF ISCHEMIC HEART DISEASE
by: V. E. Oleynikov, et al.
Published: (2015-11-01)

The Oncogenic Burden of Obesity: Mechanistic Links Between Adiposity and Gastrointestinal Cancers—A Comprehensive Narrative Review
by: Felicia Lee, et al.
Published: (2025-06-01)

ROLE OF PERIVASCULAR ADIPOSE TISSUE IN THE DEVELOPMENT OF ATHEROSCLEROTIC AND NONATHEROSCLEROTIC DISEASES
by: E. G. Uchasova, et al.
Published: (2019-10-01)

RECENT ADVANCES IN THE APPLICATION OF HIGH DOSES OF ATORVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE
by: M. V. Ezhov
Published: (2016-01-01)

A case of rhabdomyolysis after atorvastatin therapy of a liver transplant recipient receiving immunosuppressive therapy with cyclosporine
by: A. V. Shabunin, et al.
Published: (2021-06-01)

Atorvastatin: evidence base 15 years later
by: A. V. Susekov, et al.
Published: (2011-06-01)

ATORVASTATIN — 20 YEARS IN THE STRUGGLE FOR LIFE
by: N. G. Gogolashvili
Published: (2018-03-01)

Circulating prosaposin and ependymin-related protein 1 levels are correlated with insulin resistance in type 2 diabetic patients
by: Xin Ji, et al.
Published: (2025-06-01)

EFFECTS OF ATORVASTATIN ON ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETIC PATIENTS WITH DIFFERENT DURATION F THE DISEASE
by: G. A. Batrak, et al.
Published: (2015-09-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

EFFECTS OF AN EIGHT-WEEK ATORVASTATIN TREATMENT ON SPONTANEOUS CYTOKINE PRODUCTION BY THE BLOOD MONONUCLEAR LEUKOCYTES IN METABOLIC SYNDROME
by: I. D. Bespalovа, et al.
Published: (2014-11-01)

The relationship of epicardial obesity and levels of cardiac fibrosis markers
by: O. V. Gritsenko, et al.
Published: (2019-05-01)

Hypolipidemic effect of atorvastatin and phytotherapy on rat prostate - A histological study
by: Erieg A. Mohamed, et al.
Published: (2022-12-01)

Pleiotropic vasoprotective effects of high-dose atorvastatin therapy in the context of achieving the target low-density lipoprotein cholesterol in patients after myocardial infarction
by: L. I. Salyamova, et al.
Published: (2022-08-01)

Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin)
by: R. G. Oganov, et al.
Published: (2006-12-01)

MONITORING OF THE EFFICACY AND SAFETY OF HIGH-DOSE ATORVASTATIN IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
by: L. I. Salyamova, et al.
Published: (2018-05-01)

THE USE OF ATORVASTATIN FOR THE PREVENTION OF RECURRENT ATRIAL FIBRILLATION AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: S. N. Tereshchenko, et al.
Published: (2016-01-01)

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin
by: Fei Li, et al.
Published: (2025-07-01)

Efficacy of atorvastatin therapy in prevention of postoperative atrial fibrillation in patients with ischemic heart disease
by: O. A. Rubanenko
Published: (2015-11-01)

SERUM ADIPOKINES AND ADIPOKINE RECEPTORS IN COLON CANCER PATIENTS WITH METABOLOC SYNDROM
by: N. V. Yunusova, et al.
Published: (2016-02-01)